Citigroup
KYMR icon

Citigroup’s Kymera Therapeutics KYMR Stock Holding History

Citigroup’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.92M Buy
77,784
+65,520
+534% +$5.63M ﹤0.01% 1703
2026
Q1 		$1.02M Buy
12,264
+1,757
+17% +$139K ﹤0.01% 3104
2025
Q4 		$818K Buy
10,507
+3,601
+52% +$243K ﹤0.01% 3262
2025
Q3 		$391K Sell
6,906
-21,775
-76% -$982K ﹤0.01% 3695
2025
Q2 		$1.25M Sell
28,681
-52,391
-65% -$1.8M ﹤0.01% 3039
2025
Q1 		$2.22M Buy
81,072
+16,656
+26% +$607K ﹤0.01% 2605
2024
Q4 		$2.59M Buy
64,416
+29,852
+86% +$1.35M ﹤0.01% 2596
2024
Q3 		$1.64M Buy
34,564
+14,978
+76% +$661K ﹤0.01% 2840
2024
Q2 		$585K Sell
19,586
-201,325
-91% -$6.97M ﹤0.01% 3289
2024
Q1 		$8.88M Buy
220,911
+131,982
+148% +$4.72M 0.01% 1323
2023
Q4 		$2.26M Sell
88,929
-11,867
-12% -$212K ﹤0.01% 2136
2023
Q3 		$1.4M Sell
100,796
-7,772
-7% -$156K ﹤0.01% 2259
2023
Q2 		$2.5M Sell
108,568
-96,163
-47% -$2.76M ﹤0.01% 2006
2023
Q1 		$6.07M Buy
204,731
+72,647
+55% +$2.34M ﹤0.01% 1396
2022
Q4 		$3.3M Sell
132,084
-68,956
-34% -$1.84M ﹤0.01% 1715
2022
Q3 		$4.38M Buy
201,040
+10,239
+5% +$270K ﹤0.01% 1626
2022
Q2 		$3.76M Buy
190,801
+169,002
+775% +$3.95M ﹤0.01% 1697
2022
Q1 		$923K Sell
21,799
-59,852
-73% -$2.53M ﹤0.01% 3048
2021
Q4 		$5.18M Buy
81,651
+28,313
+53% +$1.65M ﹤0.01% 1803
2021
Q3 		$3.13M Sell
53,338
-30,127
-36% -$1.75M ﹤0.01% 2152
2021
Q2 		$4.05M Buy
83,465
+19,780
+31% +$859K ﹤0.01% 2082
2021
Q1 		$2.48M Buy
63,685
+61,653
+3,034% +$3.71M ﹤0.01% 2358
2020
Q4 		$126K Buy
+2,032
New +$99.1K ﹤0.01% 5351

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Citigroup's KYMR Position: Q2 2026 in Review

Citigroup increased its Kymera Therapeutics (KYMR) stake by 534% in Q2 2026, buying an estimated $5.63M and bringing the position to 77,784 shares worth $8.92M. The position accounts for ﹤0.01% of the portfolio, ranked #1703.

Citigroup first reported a position in KYMR in Q4 2020 and has held it in 23 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Citigroup held 77,784 shares of Kymera Therapeutics worth $8.92M as of Q2 2026.
  • Citigroup bought 65,520 Kymera Therapeutics shares in Q2 2026, an estimated $5.63M.
  • Kymera Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1703 holding.
  • Citigroup first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.